The Foundation for AIDS Research (amfAR) released a new issue brief, Expanding Access to Pre-Exposure Prophylaxis (PrEP) for Adolescents and Young Adults: Models for Addressing Consent, Confidentiality, and Payment Barriers. In May 2018, the U.S. Food and Drug Administration approved the once-daily oral medication Truvada as pre-exposure prophylaxis (PrEP) for adolescents to reduce the risk […]

Go to Original Post